MGO One Seven LLC increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 24.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,203 shares of the pharmaceutical company’s stock after acquiring an additional 234 shares during the period. MGO One Seven LLC’s holdings in Vertex Pharmaceuticals were worth $347,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the business. BlackRock Inc. raised its position in Vertex Pharmaceuticals by 0.4% in the third quarter. BlackRock Inc. now owns 25,243,060 shares of the pharmaceutical company’s stock worth $7,308,875,000 after acquiring an additional 105,908 shares in the last quarter. Vanguard Group Inc. raised its position in Vertex Pharmaceuticals by 1.4% in the third quarter. Vanguard Group Inc. now owns 21,132,336 shares of the pharmaceutical company’s stock worth $6,118,657,000 after acquiring an additional 293,861 shares in the last quarter. State Street Corp raised its position in Vertex Pharmaceuticals by 0.3% in the third quarter. State Street Corp now owns 12,294,791 shares of the pharmaceutical company’s stock worth $3,559,834,000 after acquiring an additional 30,742 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Vertex Pharmaceuticals by 3.9% in the third quarter. Price T Rowe Associates Inc. MD now owns 5,157,954 shares of the pharmaceutical company’s stock worth $1,493,458,000 after acquiring an additional 195,271 shares in the last quarter. Finally, Jennison Associates LLC raised its position in Vertex Pharmaceuticals by 168.3% in the third quarter. Jennison Associates LLC now owns 4,755,821 shares of the pharmaceutical company’s stock worth $1,377,000,000 after acquiring an additional 2,983,253 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.
Insider Transactions at Vertex Pharmaceuticals
In other news, Director Yuchun Lee sold 442 shares of the business’s stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $312.17, for a total transaction of $137,979.14. Following the sale, the director now directly owns 1,875 shares of the company’s stock, valued at $585,318.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Yuchun Lee sold 442 shares of the business’s stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $312.17, for a total transaction of $137,979.14. Following the sale, the director now directly owns 1,875 shares of the company’s stock, valued at $585,318.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Stuart A. Arbuckle sold 4,887 shares of the business’s stock in a transaction on Monday, February 13th. The stock was sold at an average price of $298.92, for a total value of $1,460,822.04. Following the sale, the chief operating officer now directly owns 82,003 shares in the company, valued at $24,512,336.76. The disclosure for this sale can be found here. Insiders have sold 47,952 shares of company stock valued at $14,589,935 over the last three months. Company insiders own 0.40% of the company’s stock.
Vertex Pharmaceuticals Trading Down 0.1 %
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The pharmaceutical company reported $3.76 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.65. Vertex Pharmaceuticals had a return on equity of 27.78% and a net margin of 37.20%. The company had revenue of $2.30 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the business earned $3.18 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 12.36 EPS for the current year.
Wall Street Analysts Forecast Growth
VRTX has been the subject of several research analyst reports. Sanford C. Bernstein initiated coverage on Vertex Pharmaceuticals in a research report on Tuesday, March 21st. They issued an “outperform” rating and a $344.00 price objective for the company. Canaccord Genuity Group initiated coverage on Vertex Pharmaceuticals in a research report on Wednesday, January 18th. They issued a “hold” rating and a $311.00 price target for the company. Jefferies Financial Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and set a $340.00 price target for the company. in a research report on Monday, December 19th. StockNews.com assumed coverage on Vertex Pharmaceuticals in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. Finally, Barclays increased their price objective on Vertex Pharmaceuticals from $313.00 to $342.00 and gave the company an “overweight” rating in a research note on Wednesday, February 8th. Six equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $327.30.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals, Inc is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Featured Stories
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
- FedEx Takes Flight; Analysts See More Gains Ahead
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
